Live Breaking News & Updates on Advent France Biotechnology|Page 3

Stay updated with breaking news from Advent france biotechnology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics


SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics
GAMUT
rod-cone dystrophies such as retinitis
pigmentosa
rod-cone dystrophies
today
-
Paris,
202
1 - SparingVision (the Company ), a genomic medicines company developing vision saving treatments for ocular diseases, today announces it has entered into a definitive agreement to acquire GAMUT Therapeutics ( GAMUT ), a biotechnology company pioneering a unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis pigmentosa ( RP ). The acquisition, subject to legal formalities and approval by shareholders of both companies, will be paid mostly in new SparingVision shares and is expected to close in Q2 2021. Further financial terms of the transaction are not disclosed. ....

Frankfurt Am Main , United States , France General , Olivia Manser , Amber Fennell , Deniz Dalkara , Kostenloser Wertpapierhandel , Max Planck , Davide Salvi , Priit Piip , Nathalie Trepo , Research Award For Fondation De France , Biotherapeutics Department , Ministry Of Research , Technology Review Innovators , Nanomedicine Development Center , Foundation Fighting Blindness , Paris Vision Institute , Sparingvision The Company , University Of Louis Pasteur , Consilium Strategic Communications , Chief Executive Officer , Institut De La Vision , Advent France , Operating Partner , Advent France Biotechnology ,

Advent France Biotechnology appoints Alejo Chorny, PhD, as operating partner and head of new Spanish


Search jobs
17-Mar-2021
Advent France Biotechnology appoints Alejo Chorny, PhD, as operating partner and head of new Spanish operations
Paris, France, and Barcelona, Spain, March 17, 2021 – Advent France Biotechnology (AFB), an AMF-regulated investment company dedicated to life sciences, today announces the appointment of Alejo Chorny, PhD, as operating partner for Spain. His strong scientific background and experience in tech transfer, business development and project evaluation are the perfect blend to develop AFB’s activities in the region. Chorny’s main business objective will be securing a strong, reliable foothold within Spanish early-stage therapeutic projects and exploring the wealth of opportunities for potential investments. ....

New York , United States , France General , Rockefeller University , Comunidad Autonoma De Cataluna , Alain Huriez , Alejo Chorny , Icahn School Of Medicine At Mount Sinai , Advent France Biotechnology , Celdara Medical , Experimental Medicine , Icahn School , Mount Sinai , Advent France , Myotonic Dystrophy Type , France Biotechnology , Matthieu Coutet , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , ராக்ஃபெல்லர் பல்கலைக்கழகம் , காமுனிடட தன்னாட்சி டி கடலுள் , இக்ஹ்ன் பள்ளி ஆஃப் மருந்து இல் ஏற்ற சினை , சோதனை மருந்து , இக்ஹ்ன் பள்ளி , ஏற்ற சினை ,

AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators


AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators
Company expands leadership team with CMO Philippe Wiesel, CBO Paul van der Horst and CFO Tolga Hassan
AgomAb Therapeutics N.V. announced today the closing of a $74
million Series B financing round led by Redmile Group, with participation from Cormorant Asset Management. All previous investors also participated in the round, including Advent France Biotechnology, Andera Partners, Boehringer Ingelheim Venture Fund, Omnes Capital, Pontifax, and V-Bio Ventures. The proceeds of the Series B will be used to fund clinical proof of concept of the lead program AGMB-101, an HGF-mimetic agonistic antibody, which is currently progressing through IND-enabling studies. The capital will also support further growth of the company s pipeline of drug candidates designed to modulate regenerative pathways to induce functional organ recovery in acute and chronic diseases. In conjunction with ....

Tolga Hassan , Kostenloser Wertpapierhandel , Tim Knotnerus , Laura Mittmann , Philippe Wiesel , John Haurum , Redmile Group , Head Of Corporate Development At Galapagos , Trophic Communications , Boehringer Ingelheim Venture Fund , Cormorant Asset , Advent France Biotechnology , Andera Partners , Omnes Capital , Chief Executive Officer , Hepatocyte Growth Factor , Chief Medical Officer , Chief Business , Corporate Development , Chief Financial Officer , Agomab Therapeutics , Stephanie May , டோல்கா ஹாசன் , தலை ஆஃப் பெருநிறுவன வளர்ச்சி இல் க்யாலபாகொஸ் , போஹெரிங்கர் இஂகல்‌ஹைம் துணிகர நிதி , கர்மரண்ட் சொத்து ,